Rapid qualitative and quantitative analysis of T-cell responses in HIV-1-infected individuals receiving successful HAART and HIV-1 sero-negative controls:: Concomitant assessment of perforin, IFN-γ and IL-4 secretion

被引:12
作者
Burton, CT [1 ]
Gotch, F [1 ]
Imami, N [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Chelsea & Westminster Hosp, Dept Immunol, London SW10 9NH, England
基金
英国医学研究理事会; 英国惠康基金;
关键词
lymphocyte responses; highly active antiretroviral therapy (HAART); interferon gamma; perforin; interleukin-4; T-cell memory; T-cell anergy;
D O I
10.1016/j.jim.2005.11.005
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The enzyme-linked inummospot (ELIspot) assay is a highly sensitive and valuable tool for determining the frequency of cytokine-secreting T cells. It is essential to determine both frequencies and functional capabilities of antigen-specific T cells, including cytokine secretion, degranulation, and cytotoxicity in order to obtain a faller picture of the immune status of an individual. We describe here for the first time a perforin-release ELIspot assay which, when used in combination with IFN-gamma and IL-4 ELIspots, permits rapid assessment of these functional parameters for antigen-specific T cells. Whole antigen or peptides from HIV-1, recall and other viral antigens were used for in vitro stimulation. Anti-HIV-1 responses in treated chronically infected individuals were weak, both in terms of perform and IFN-gamma production. Tetanus toxoid stimulation was associated with moderate perforin release and a predominantly type-2 IL-4 producing response, whilst herpes simplex virus antigen stimulation resulted in perforin release but only a weak type-1 IFN-gamma response. Anti-cytomegalovirus responses generated high levels of perform in conjunction with IFN-gamma. Cytokines IL-2 and IL-12/IL-15 induced perform release coupled with an IFN-gamma type-1 response. Perform release strongly correlated with IFN-gamma production to individual influenza, Epstein-Barr virus or cytomegalovirus MHC class I restricted peptides, in an HIV-1 sero-negative cohort, indicating a cytolytic type-1 CD8(+) T-cell response. Evaluation of immunogenicity and putative efficacy of candidate vaccines using IFN-gamma will not be as informative alone as when combined with perforin and IL-4 evaluations, which allow assessment of specific cytotoxic potential without extensive cell culture. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:216 / 230
页数:15
相关论文
共 34 条
[1]   Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia [J].
Allen, TM ;
O'Connor, DH ;
Jing, PC ;
Dzuris, JL ;
Mothé, BR ;
Vogel, TU ;
Dunphy, E ;
Liebl, ME ;
Emerson, C ;
Wilson, N ;
Kunstman, KJ ;
Wang, XC ;
Allison, DB ;
Hughes, AL ;
Desrosiers, RC ;
Altman, JD ;
Wolinsky, SM ;
Sette, A ;
Watkins, DI .
NATURE, 2000, 407 (6802) :386-390
[2]   HIV-specific CD8+ T cells produce antiviral cytokines but are impaired in cytolytic function [J].
Appay, V ;
Nixon, DF ;
Donahoe, SM ;
Gillespie, GMA ;
Dong, T ;
King, A ;
Ogg, GS ;
Spiegel, HML ;
Conlon, C ;
Spina, CA ;
Havlir, DV ;
Richman, DD ;
Waters, A ;
Easterbrook, P ;
McMichael, AJ ;
Rowland-Jones, SL .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (01) :63-75
[3]   Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with ≤250/μL CD4 T cells and undetectable plasma virus load [J].
Arnó, A ;
Ruiz, L ;
Juan, M ;
Jou, A ;
Balagué, M ;
Zayat, MK ;
Marfil, S ;
Martínez-Picado, J ;
Martínez, MA ;
Romeu, J ;
Pujol-Borrell, R ;
Lane, C ;
Clotet, B .
JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (01) :56-60
[4]   Restoration of the immune system with anti-retroviral therapy [J].
Autran, B ;
Carcelaint, G ;
Li, TS ;
Gorochov, G ;
Blanc, C ;
Renaud, M ;
Durali, M ;
Mathez, D ;
Calvez, V ;
Leibowitch, J ;
Katlama, C ;
Debré, P .
IMMUNOLOGY LETTERS, 1999, 66 (1-3) :207-211
[5]   Sensitive and viable identification of antigen-specific CD8+T cells by a flow cytometric assay for degranulation [J].
Betts, MR ;
Brenchley, JM ;
Price, DA ;
De Rosa, SC ;
Douek, DC ;
Roederer, M ;
Koup, RA .
JOURNAL OF IMMUNOLOGICAL METHODS, 2003, 281 (1-2) :65-78
[6]  
BRUNNER KT, 1968, IMMUNOLOGY, V14, P181
[7]   Skewed maturation of memory HIV-specific CD8 T lymphocytes [J].
Champagne, P ;
Ogg, GS ;
King, AS ;
Knabenhans, C ;
Ellefsen, K ;
Nobile, M ;
Appay, V ;
Rizzardi, GP ;
Fleury, S ;
Lipp, M ;
Förster, R ;
Rowland-Jones, S ;
Sékaly, RP ;
McMichael, AJ ;
Pantaleo, G .
NATURE, 2001, 410 (6824) :106-111
[8]   A T(H)1-]T(H)2 SWITCH IS A CRITICAL STEP IN THE ETIOLOGY OF HIV-INFECTION [J].
CLERICI, M ;
SHEARER, GM .
IMMUNOLOGY TODAY, 1993, 14 (03) :107-110
[9]   A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays [J].
Currier, JR ;
Kuta, EG ;
Turk, E ;
Earhart, LB ;
Loomis-Price, L ;
Janetzki, S ;
Ferrari, G ;
Birx, DL ;
Cox, JH .
JOURNAL OF IMMUNOLOGICAL METHODS, 2002, 260 (1-2) :157-172
[10]   Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy - A randomized controlled trial [J].
Davey, RT ;
Murphy, RL ;
Graziano, FM ;
Boswell, SL ;
Pavia, AT ;
Cancio, M ;
Nadler, JP ;
Chaitt, DG ;
Dewar, RL ;
Sahner, DK ;
Duliege, AM ;
Capra, WB ;
Leong, WP ;
Giedlin, MA ;
Lane, HC ;
Kahn, JO .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (02) :183-189